130 related articles for article (PubMed ID: 38218799)
1. Implementing the time-to-event continual reassessment method in the presence of partial orders in a phase I head and neck cancer trial.
Patel A; Brock K; Slade D; Gaunt C; Kong A; Mehanna H; Billingham L; Gaunt P
BMC Med Res Methodol; 2024 Jan; 24(1):11. PubMed ID: 38218799
[TBL] [Abstract][Full Text] [Related]
2. Using the time-to-event continual reassessment method in the presence of partial orders.
Wages NA; Conaway MR; O'Quigley J
Stat Med; 2013 Jan; 32(1):131-41. PubMed ID: 22806898
[TBL] [Abstract][Full Text] [Related]
3. A comparison of phase I dose-finding designs in clinical trials with monotonicity assumption violation.
Abbas R; Rossoni C; Jaki T; Paoletti X; Mozgunov P
Clin Trials; 2020 Oct; 17(5):522-534. PubMed ID: 32631095
[TBL] [Abstract][Full Text] [Related]
4. Practicalities in running early-phase trials using the time-to-event continual reassessment method (TiTE-CRM) for interventions with long toxicity periods using two radiotherapy oncology trials as examples.
van Werkhoven E; Hinsley S; Frangou E; Holmes J; de Haan R; Hawkins M; Brown S; Love SB
BMC Med Res Methodol; 2020 Jun; 20(1):162. PubMed ID: 32571298
[TBL] [Abstract][Full Text] [Related]
5. A new pragmatic design for dose escalation in phase 1 clinical trials using an adaptive continual reassessment method.
North B; Kocher HM; Sasieni P
BMC Cancer; 2019 Jun; 19(1):632. PubMed ID: 31242873
[TBL] [Abstract][Full Text] [Related]
6. Dose-finding design for multi-drug combinations.
Wages NA; Conaway MR; O'Quigley J
Clin Trials; 2011 Aug; 8(4):380-9. PubMed ID: 21652689
[TBL] [Abstract][Full Text] [Related]
7. Specifications of a continual reassessment method design for phase I trials of combined drugs.
Wages NA; Conaway MR
Pharm Stat; 2013; 12(4):217-24. PubMed ID: 23729323
[TBL] [Abstract][Full Text] [Related]
8. Consistency of the CRM when the dose-toxicity curve is not monotone and its application to the POCRM.
Saha PT; Fine JP; Ivanova A
Stat Med; 2021 Apr; 40(8):2073-2082. PubMed ID: 33588519
[TBL] [Abstract][Full Text] [Related]
9. Practical modifications to the time-to-event continual reassessment method for phase I cancer trials with fast patient accrual and late-onset toxicities.
Polley MY
Stat Med; 2011 Jul; 30(17):2130-43. PubMed ID: 21590790
[TBL] [Abstract][Full Text] [Related]
10. Quasi-partial order continual reassessment method: Applying toxicity scores to cancer dose-finding drug combination trials.
O'Connell NS; Wages NA; Garrett-Mayer E
Contemp Clin Trials; 2023 Feb; 125():107050. PubMed ID: 36529437
[TBL] [Abstract][Full Text] [Related]
11. Dose-finding clinical trial design for ordinal toxicity grades using the continuation ratio model: an extension of the continual reassessment method.
Van Meter EM; Garrett-Mayer E; Bandyopadhyay D
Clin Trials; 2012 Jun; 9(3):303-13. PubMed ID: 22547420
[TBL] [Abstract][Full Text] [Related]
12. Continual reassessment method for partial ordering.
Wages NA; Conaway MR; O'Quigley J
Biometrics; 2011 Dec; 67(4):1555-63. PubMed ID: 21361888
[TBL] [Abstract][Full Text] [Related]
13. How to design a dose-finding study using the continual reassessment method.
Wheeler GM; Mander AP; Bedding A; Brock K; Cornelius V; Grieve AP; Jaki T; Love SB; Odondi L; Weir CJ; Yap C; Bond SJ
BMC Med Res Methodol; 2019 Jan; 19(1):18. PubMed ID: 30658575
[TBL] [Abstract][Full Text] [Related]
14. Two-stage subgroup-specific time-to-event (2S-Sub-TITE): An adaptive two-stage time-to-toxicity design for subgroup-specific dose finding in phase I oncology trials.
McGovern A; Chapple AG; Ma C
Pharm Stat; 2022 Nov; 21(6):1138-1148. PubMed ID: 35560864
[TBL] [Abstract][Full Text] [Related]
15. Assessment of various continual reassessment method models for dose-escalation phase 1 oncology clinical trials: using real clinical data and simulation studies.
James GD; Symeonides S; Marshall J; Young J; Clack G
BMC Cancer; 2021 Jan; 21(1):7. PubMed ID: 33402104
[TBL] [Abstract][Full Text] [Related]
16. The superiority of the time-to-event continual reassessment method to the rolling six design in pediatric oncology Phase I trials.
Zhao L; Lee J; Mody R; Braun TM
Clin Trials; 2011 Aug; 8(4):361-9. PubMed ID: 21610004
[TBL] [Abstract][Full Text] [Related]
17. Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method.
Normolle D; Lawrence T
J Clin Oncol; 2006 Sep; 24(27):4426-33. PubMed ID: 16983110
[TBL] [Abstract][Full Text] [Related]
18. Rolling continual reassessment method with overdose control: An efficient and safe dose escalation design.
Zhu J; Sabanés Bové D; Liao Z; Beyer U; Yung G; Sarkar S
Contemp Clin Trials; 2021 Aug; 107():106436. PubMed ID: 34000410
[TBL] [Abstract][Full Text] [Related]
19. Subgroup-specific dose finding in phase I clinical trials based on time to toxicity allowing adaptive subgroup combination.
Chapple AG; Thall PF
Pharm Stat; 2018 Nov; 17(6):734-749. PubMed ID: 30112806
[TBL] [Abstract][Full Text] [Related]
20. Dose-finding design and benchmark for a right censored endpoint.
Andrillon A; Chevret S; Lee SM; Biard L
J Biopharm Stat; 2020 Nov; 30(6):948-963. PubMed ID: 33222634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
